The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...

Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug Administration. Compounded copycat drugs containing tirzepatide ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a study ...

There have been few studies that have been able to take a comprehensive look at how these medications, which include Ozempic, ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

People taking Zepbound lost an average of 45 pounds and ... Previous studies have found that the obesity drug (marketed as Mounjaro for type 2 diabetes) also leads to significant improvements ...